img

Global Anti-VEGF Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Anti-VEGF Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Anti-VEGF Drug report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Anti-VEGF Drug market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Age-related Macular Degeneration and Macular Edema Following Retinal Vein Occlusion are the major drivers for the industry.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anti-VEGF Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


F. Hoffmann-La Roche Ltd
Amgen Inc
Pfizer, Inc
Xbrane Biopharma AB
Allergan
Bayer AG
Regeneron Pharmaceuticals Inc.
Viatris Inc
Segment by Type
Avastin
Lucentis
Eylea

Segment by Application


Age-related Macular Degeneration
Macular Edema Following Retinal Vein Occlusion
Diabetic Macular Edema
Diabetic Retinopathy

Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Anti-VEGF Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Anti-VEGF Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Anti-VEGF Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Anti-VEGF Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Anti-VEGF Drug introduction, etc. Anti-VEGF Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Anti-VEGF Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Anti-VEGF Drug Market Overview
1.1 Anti-VEGF Drug Product Overview
1.2 Anti-VEGF Drug Market Segment by Type
1.2.1 Avastin
1.2.2 Lucentis
1.2.3 Eylea
1.3 Global Anti-VEGF Drug Market Size by Type
1.3.1 Global Anti-VEGF Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Anti-VEGF Drug Historic Market Size Review by Type (2018-2024)
1.3.3 Global Anti-VEGF Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Anti-VEGF Drug Sales Breakdown by Type (2018-2024)
1.4.2 Europe Anti-VEGF Drug Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Anti-VEGF Drug Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Anti-VEGF Drug Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Anti-VEGF Drug Sales Breakdown by Type (2018-2024)
2 Global Anti-VEGF Drug Market Competition by Company
2.1 Global Top Players by Anti-VEGF Drug Sales (2018-2024)
2.2 Global Top Players by Anti-VEGF Drug Revenue (2018-2024)
2.3 Global Top Players by Anti-VEGF Drug Price (2018-2024)
2.4 Global Top Manufacturers Anti-VEGF Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Anti-VEGF Drug Market Competitive Situation and Trends
2.5.1 Anti-VEGF Drug Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Anti-VEGF Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Anti-VEGF Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Anti-VEGF Drug Market
2.8 Key Manufacturers Anti-VEGF Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Anti-VEGF Drug Status and Outlook by Region
3.1 Global Anti-VEGF Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Anti-VEGF Drug Historic Market Size by Region
3.2.1 Global Anti-VEGF Drug Sales in Volume by Region (2018-2024)
3.2.2 Global Anti-VEGF Drug Sales in Value by Region (2018-2024)
3.2.3 Global Anti-VEGF Drug Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Anti-VEGF Drug Forecasted Market Size by Region
3.3.1 Global Anti-VEGF Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Anti-VEGF Drug Sales in Value by Region (2024-2029)
3.3.3 Global Anti-VEGF Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Anti-VEGF Drug by Application
4.1 Anti-VEGF Drug Market Segment by Application
4.1.1 Age-related Macular Degeneration
4.1.2 Macular Edema Following Retinal Vein Occlusion
4.1.3 Diabetic Macular Edema
4.1.4 Diabetic Retinopathy
4.2 Global Anti-VEGF Drug Market Size by Application
4.2.1 Global Anti-VEGF Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Anti-VEGF Drug Historic Market Size Review by Application (2018-2024)
4.2.3 Global Anti-VEGF Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Anti-VEGF Drug Sales Breakdown by Application (2018-2024)
4.3.2 Europe Anti-VEGF Drug Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Anti-VEGF Drug Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Anti-VEGF Drug Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Anti-VEGF Drug Sales Breakdown by Application (2018-2024)
5 North America Anti-VEGF Drug by Country
5.1 North America Anti-VEGF Drug Historic Market Size by Country
5.1.1 North America Anti-VEGF Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Anti-VEGF Drug Sales in Volume by Country (2018-2024)
5.1.3 North America Anti-VEGF Drug Sales in Value by Country (2018-2024)
5.2 North America Anti-VEGF Drug Forecasted Market Size by Country
5.2.1 North America Anti-VEGF Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Anti-VEGF Drug Sales in Value by Country (2024-2029)
6 Europe Anti-VEGF Drug by Country
6.1 Europe Anti-VEGF Drug Historic Market Size by Country
6.1.1 Europe Anti-VEGF Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Anti-VEGF Drug Sales in Volume by Country (2018-2024)
6.1.3 Europe Anti-VEGF Drug Sales in Value by Country (2018-2024)
6.2 Europe Anti-VEGF Drug Forecasted Market Size by Country
6.2.1 Europe Anti-VEGF Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Anti-VEGF Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Anti-VEGF Drug by Region
7.1 Asia-Pacific Anti-VEGF Drug Historic Market Size by Region
7.1.1 Asia-Pacific Anti-VEGF Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Anti-VEGF Drug Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Anti-VEGF Drug Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Anti-VEGF Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Anti-VEGF Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Anti-VEGF Drug Sales in Value by Region (2024-2029)
8 Latin America Anti-VEGF Drug by Country
8.1 Latin America Anti-VEGF Drug Historic Market Size by Country
8.1.1 Latin America Anti-VEGF Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Anti-VEGF Drug Sales in Volume by Country (2018-2024)
8.1.3 Latin America Anti-VEGF Drug Sales in Value by Country (2018-2024)
8.2 Latin America Anti-VEGF Drug Forecasted Market Size by Country
8.2.1 Latin America Anti-VEGF Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Anti-VEGF Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Anti-VEGF Drug by Country
9.1 Middle East and Africa Anti-VEGF Drug Historic Market Size by Country
9.1.1 Middle East and Africa Anti-VEGF Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Anti-VEGF Drug Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Anti-VEGF Drug Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Anti-VEGF Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Anti-VEGF Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Anti-VEGF Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 F. Hoffmann-La Roche Ltd
10.1.1 F. Hoffmann-La Roche Ltd Company Information
10.1.2 F. Hoffmann-La Roche Ltd Introduction and Business Overview
10.1.3 F. Hoffmann-La Roche Ltd Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2024)
10.1.4 F. Hoffmann-La Roche Ltd Anti-VEGF Drug Products Offered
10.1.5 F. Hoffmann-La Roche Ltd Recent Development
10.2 Amgen Inc
10.2.1 Amgen Inc Company Information
10.2.2 Amgen Inc Introduction and Business Overview
10.2.3 Amgen Inc Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Amgen Inc Anti-VEGF Drug Products Offered
10.2.5 Amgen Inc Recent Development
10.3 Pfizer, Inc
10.3.1 Pfizer, Inc Company Information
10.3.2 Pfizer, Inc Introduction and Business Overview
10.3.3 Pfizer, Inc Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Pfizer, Inc Anti-VEGF Drug Products Offered
10.3.5 Pfizer, Inc Recent Development
10.4 Xbrane Biopharma AB
10.4.1 Xbrane Biopharma AB Company Information
10.4.2 Xbrane Biopharma AB Introduction and Business Overview
10.4.3 Xbrane Biopharma AB Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Xbrane Biopharma AB Anti-VEGF Drug Products Offered
10.4.5 Xbrane Biopharma AB Recent Development
10.5 Allergan
10.5.1 Allergan Company Information
10.5.2 Allergan Introduction and Business Overview
10.5.3 Allergan Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Allergan Anti-VEGF Drug Products Offered
10.5.5 Allergan Recent Development
10.6 Bayer AG
10.6.1 Bayer AG Company Information
10.6.2 Bayer AG Introduction and Business Overview
10.6.3 Bayer AG Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Bayer AG Anti-VEGF Drug Products Offered
10.6.5 Bayer AG Recent Development
10.7 Regeneron Pharmaceuticals Inc.
10.7.1 Regeneron Pharmaceuticals Inc. Company Information
10.7.2 Regeneron Pharmaceuticals Inc. Introduction and Business Overview
10.7.3 Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Products Offered
10.7.5 Regeneron Pharmaceuticals Inc. Recent Development
10.8 Viatris Inc
10.8.1 Viatris Inc Company Information
10.8.2 Viatris Inc Introduction and Business Overview
10.8.3 Viatris Inc Anti-VEGF Drug Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Viatris Inc Anti-VEGF Drug Products Offered
10.8.5 Viatris Inc Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Anti-VEGF Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Anti-VEGF Drug Industrial Chain Analysis
11.4 Anti-VEGF Drug Market Dynamics
11.4.1 Anti-VEGF Drug Industry Trends
11.4.2 Anti-VEGF Drug Market Drivers
11.4.3 Anti-VEGF Drug Market Challenges
11.4.4 Anti-VEGF Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Anti-VEGF Drug Distributors
12.3 Anti-VEGF Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Avastin
Table 2. Major Company of Lucentis
Table 3. Major Company of Eylea
Table 4. Global Anti-VEGF Drug Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Anti-VEGF Drug Sales by Type (2018-2024) & (K Units)
Table 6. Global Anti-VEGF Drug Sales Market Share in Volume by Type (2018-2024)
Table 7. Global Anti-VEGF Drug Sales by Type (2018-2024) & (US& Million)
Table 8. Global Anti-VEGF Drug Market Share in Value by Type (2018-2024)
Table 9. Global Anti-VEGF Drug Price by Type (2018-2024) & (US$/Unit)
Table 10. Global Anti-VEGF Drug Sales by Type (2024-2029) & (K Units)
Table 11. Global Anti-VEGF Drug Sales Market Share in Volume by Type (2024-2029)
Table 12. Global Anti-VEGF Drug Sales by Type (2024-2029) & (US$ Million)
Table 13. Global Anti-VEGF Drug Sales Market Share in Value by Type (2024-2029)
Table 14. Global Anti-VEGF Drug Price by Type (2024-2029) & (US$/Unit)
Table 15. North America Anti-VEGF Drug Sales by Type (2018-2024) & (K Units)
Table 16. North America Anti-VEGF Drug Sales by Type (2018-2024) & (US$ Million)
Table 17. Europe Anti-VEGF Drug Sales (K Units) by Type (2018-2024)
Table 18. Europe Anti-VEGF Drug Sales by Type (2018-2024) & (US$ Million)
Table 19. Asia-Pacific Anti-VEGF Drug Sales (K Units) by Type (2018-2024)
Table 20. Asia-Pacific Anti-VEGF Drug Sales by Type (2018-2024) & (US$ Million)
Table 21. Latin America Anti-VEGF Drug Sales (K Units) by Type (2018-2024)
Table 22. Latin America Anti-VEGF Drug Sales by Type (2018-2024) & (US$ Million)
Table 23. Middle East and Africa Anti-VEGF Drug Sales (K Units) by Type (2018-2024)
Table 24. Middle East and Africa Anti-VEGF Drug Sales by Type (2018-2024) & (US$ Million)
Table 25. Global Anti-VEGF Drug Sales by Company (2018-2024) & (K Units)
Table 26. Global Anti-VEGF Drug Sales Share by Company (2018-2024)
Table 27. Global Anti-VEGF Drug Revenue by Company (2018-2024) & (US$ Million)
Table 28. Global Anti-VEGF Drug Revenue Share by Company (2018-2024)
Table 29. Global Market Anti-VEGF Drug Price by Company (2018-2024) & (US$/Unit)
Table 30. Global Anti-VEGF Drug Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 31. Global Anti-VEGF Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 32. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Anti-VEGF Drug as of 2022)
Table 33. Date of Key Manufacturers Enter into Anti-VEGF Drug Market
Table 34. Key Manufacturers Anti-VEGF Drug Product Type
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Anti-VEGF Drug Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 37. Global Anti-VEGF Drug Sales by Region (2018-2024) & (K Units)
Table 38. Global Anti-VEGF Drug Sales Market Share in Volume by Region (2018-2024)
Table 39. Global Anti-VEGF Drug Sales by Region (2018-2024) & (US$ Million)
Table 40. Global Anti-VEGF Drug Sales Market Share in Value by Region (2018-2024)
Table 41. Global Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 42. Global Anti-VEGF Drug Sales by Region (2024-2029) & (K Units)
Table 43. Global Anti-VEGF Drug Sales Market Share in Volume by Region (2024-2029)
Table 44. Global Anti-VEGF Drug Sales by Region (2024-2029) & (US$ Million)
Table 45. Global Anti-VEGF Drug Sales Market Share in Value by Region (2024-2029)
Table 46. Global Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2029)
Table 47. Global Anti-VEGF Drug Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 48. Global Anti-VEGF Drug Sales by Application (2018-2024) & (K Units)
Table 49. Global Anti-VEGF Drug Sales Market Share in Volume by Application (2018-2024)
Table 50. Global Anti-VEGF Drug Sales by Application (2018-2024) & (US$ Million)
Table 51. Global Anti-VEGF Drug Sales Market Share in Value by Application (2018-2024)
Table 52. Global Anti-VEGF Drug Price by Application (2018-2024) & (US$/Unit)
Table 53. Global Anti-VEGF Drug Sales by Application (2024-2029) & (K Units)
Table 54. Global Anti-VEGF Drug Sales Market Share in Volume by Application (2024-2029)
Table 55. Global Anti-VEGF Drug Sales by Application (2024-2029) & (US$ Million)
Table 56. Global Anti-VEGF Drug Sales Market Share in Value by Application (2024-2029)
Table 57. Global Anti-VEGF Drug Price by Application (2024-2029) & (US$/Unit)
Table 58. North America Anti-VEGF Drug Sales by Application (2018-2024) (K Units)
Table 59. North America Anti-VEGF Drug Sales by Application (2018-2024) & (US$ Million)
Table 60. Europe Anti-VEGF Drug Sales by Application (2018-2024) (K Units)
Table 61. Europe Anti-VEGF Drug Sales by Application (2018-2024) & (US$ Million)
Table 62. Asia-Pacific Anti-VEGF Drug Sales by Application (2018-2024) (K Units)
Table 63. Asia-Pacific Anti-VEGF Drug Sales by Application (2018-2024) & (US$ Million)
Table 64. Latin America Anti-VEGF Drug Sales by Application (2018-2024) (K Units)
Table 65. Latin America Anti-VEGF Drug Sales by Application (2018-2024) & (US$ Million)
Table 66. Middle East and Africa Anti-VEGF Drug Sales by Application (2018-2024) (K Units)
Table 67. Middle East and Africa Anti-VEGF Drug Sales by Application (2018-2024) & (US$ Million)
Table 68. North America Anti-VEGF Drug Sales by Country (2018-2024) & (K Units)
Table 69. North America Anti-VEGF Drug Sales Market Share in Volume by Country (2018-2024)
Table 70. North America Anti-VEGF Drug Sales by Country (2018-2024) & (US$ Million)
Table 71. North America Anti-VEGF Drug Sales Market Share in Value by Country (2018-2024)
Table 72. North America Anti-VEGF Drug Sales by Country (2024-2029) & (K Units)
Table 73. North America Anti-VEGF Drug Sales Market Share in Volume by Country (2024-2029)
Table 74. North America Anti-VEGF Drug Sales by Country (2024-2029) & (US$ Million)
Table 75. North America Anti-VEGF Drug Sales Market Share in Value by Country (2024-2029)
Table 76. Europe Anti-VEGF Drug Sales by Country (2018-2024) & (K Units)
Table 77. Europe Anti-VEGF Drug Sales Market Share in Volume by Country (2018-2024)
Table 78. Europe Anti-VEGF Drug Sales by Country (2018-2024) & (US$ Million)
Table 79. Europe Anti-VEGF Drug Sales Market Share in Value by Country (2018-2024)
Table 80. Europe Anti-VEGF Drug Sales by Country (2024-2029) & (K Units)
Table 81. Europe Anti-VEGF Drug Sales Market Share in Volume by Country (2024-2029)
Table 82. Europe Anti-VEGF Drug Sales by Country (2024-2029) & (US$ Million)
Table 83. Europe Anti-VEGF Drug Sales Market Share in Value by Country (2024-2029)
Table 84. Asia-Pacific Anti-VEGF Drug Sales by Region (2018-2024) & (K Units)
Table 85. Asia-Pacific Anti-VEGF Drug Sales Market Share in Volume by Region (2018-2024)
Table 86. Asia-Pacific Anti-VEGF Drug Sales by Region (2018-2024) & (US$ Million)
Table 87. Asia-Pacific Anti-VEGF Drug Sales Market Share in Value by Region (2018-2024)
Table 88. Asia-Pacific Anti-VEGF Drug Sales by Region (2024-2029) & (K Units)
Table 89. Asia-Pacific Anti-VEGF Drug Sales Market Share in Volume by Region (2024-2029)
Table 90. Asia-Pacific Anti-VEGF Drug Sales by Region (2024-2029) & (US$ Million)
Table 91. Asia-Pacific Anti-VEGF Drug Sales Market Share in Value by Region (2024-2029)
Table 92. Latin America Anti-VEGF Drug Sales by Country (2018-2024) & (K Units)
Table 93. Latin America Anti-VEGF Drug Sales Market Share in Volume by Country (2018-2024)
Table 94. Latin America Anti-VEGF Drug Sales by Country (2018-2024) & (US$ Million)
Table 95. Latin America Anti-VEGF Drug Sales Market Share in Value by Country (2018-2024)
Table 96. Latin America Anti-VEGF Drug Sales by Country (2024-2029) & (K Units)
Table 97. Latin America Anti-VEGF Drug Sales Market Share in Volume by Country (2024-2029)
Table 98. Latin America Anti-VEGF Drug Sales by Country (2024-2029) & (US$ Million)
Table 99. Latin America Anti-VEGF Drug Sales Market Share in Value by Country (2024-2029)
Table 100. Middle East and Africa Anti-VEGF Drug Sales by Country (2018-2024) & (K Units)
Table 101. Middle East and Africa Anti-VEGF Drug Sales Market Share in Volume by Country (2018-2024)
Table 102. Middle East and Africa Anti-VEGF Drug Sales by Country (2018-2024) & (US$ Million)
Table 103. Middle East and Africa Anti-VEGF Drug Sales Market Share in Value by Country (2018-2024)
Table 104. Middle East and Africa Anti-VEGF Drug Sales by Country (2024-2029) & (K Units)
Table 105. Middle East and Africa Anti-VEGF Drug Sales Market Share in Volume by Country (2024-2029)
Table 106. Middle East and Africa Anti-VEGF Drug Sales by Country (2024-2029) & (US$ Million)
Table 107. Middle East and Africa Anti-VEGF Drug Sales Market Share in Value by Country (2024-2029)
Table 108. F. Hoffmann-La Roche Ltd Company Information
Table 109. F. Hoffmann-La Roche Ltd Introduction and Business Overview
Table 110. F. Hoffmann-La Roche Ltd Anti-VEGF Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 111. F. Hoffmann-La Roche Ltd Anti-VEGF Drug Product
Table 112. F. Hoffmann-La Roche Ltd Recent Development
Table 113. Amgen Inc Company Information
Table 114. Amgen Inc Introduction and Business Overview
Table 115. Amgen Inc Anti-VEGF Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 116. Amgen Inc Anti-VEGF Drug Product
Table 117. Amgen Inc Recent Development
Table 118. Pfizer, Inc Company Information
Table 119. Pfizer, Inc Introduction and Business Overview
Table 120. Pfizer, Inc Anti-VEGF Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 121. Pfizer, Inc Anti-VEGF Drug Product
Table 122. Pfizer, Inc Recent Development
Table 123. Xbrane Biopharma AB Company Information
Table 124. Xbrane Biopharma AB Introduction and Business Overview
Table 125. Xbrane Biopharma AB Anti-VEGF Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 126. Xbrane Biopharma AB Anti-VEGF Drug Product
Table 127. Xbrane Biopharma AB Recent Development
Table 128. Allergan Company Information
Table 129. Allergan Introduction and Business Overview
Table 130. Allergan Anti-VEGF Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 131. Allergan Anti-VEGF Drug Product
Table 132. Allergan Recent Development
Table 133. Bayer AG Company Information
Table 134. Bayer AG Introduction and Business Overview
Table 135. Bayer AG Anti-VEGF Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 136. Bayer AG Anti-VEGF Drug Product
Table 137. Bayer AG Recent Development
Table 138. Regeneron Pharmaceuticals Inc. Company Information
Table 139. Regeneron Pharmaceuticals Inc. Introduction and Business Overview
Table 140. Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 141. Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Product
Table 142. Regeneron Pharmaceuticals Inc. Recent Development
Table 143. Viatris Inc Company Information
Table 144. Viatris Inc Introduction and Business Overview
Table 145. Viatris Inc Anti-VEGF Drug Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 146. Viatris Inc Anti-VEGF Drug Product
Table 147. Viatris Inc Recent Development
Table 148. Key Raw Materials Lists
Table 149. Raw Materials Key Suppliers Lists
Table 150. Anti-VEGF Drug Market Trends
Table 151. Anti-VEGF Drug Market Drivers
Table 152. Anti-VEGF Drug Market Challenges
Table 153. Anti-VEGF Drug Market Restraints
Table 154. Anti-VEGF Drug Distributors List
Table 155. Anti-VEGF Drug Downstream Customers
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-VEGF Drug Product Picture
Figure 2. Global Anti-VEGF Drug Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Anti-VEGF Drug Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global Anti-VEGF Drug Sales Status and Outlook (2018-2029) & (K Units)
Figure 5. Product Picture of Avastin
Figure 6. Global Avastin Sales YoY Growth (2018-2029) & (K Units)
Figure 7. Product Picture of Lucentis
Figure 8. Global Lucentis Sales YoY Growth (2018-2029) & (K Units)
Figure 9. Product Picture of Eylea
Figure 10. Global Eylea Sales YoY Growth (2018-2029) & (K Units)
Figure 11. Global Anti-VEGF Drug Sales by Type (2018-2029) & (US$ Million)
Figure 12. Global Anti-VEGF Drug Sales Market Share by Type in 2022 & 2029
Figure 13. North America Anti-VEGF Drug Sales Market Share in Volume by Type in 2022
Figure 14. North America Anti-VEGF Drug Sales Market Share in Value by Type in 2022
Figure 15. Europe Anti-VEGF Drug Sales Market Share in Volume by Type in 2022
Figure 16. Europe Anti-VEGF Drug Sales Market Share in Value by Type in 2022
Figure 17. Asia-Pacific Anti-VEGF Drug Sales Market Share in Volume by Type in 2022
Figure 18. Asia-Pacific Anti-VEGF Drug Sales Market Share in Value by Type in 2022
Figure 19. Latin America Anti-VEGF Drug Sales Market Share in Volume by Type in 2022
Figure 20. Latin America Anti-VEGF Drug Sales Market Share in Value by Type in 2022
Figure 21. Middle East and Africa Anti-VEGF Drug Sales Market Share in Volume by Type in 2022
Figure 22. Middle East and Africa Anti-VEGF Drug Sales Market Share in Value by Type in 2022
Figure 23. The 5 and 10 Largest Manufacturers in the World: Market Share by Anti-VEGF Drug Sales in 2022
Figure 24. The 5 and 10 Largest Manufacturers in the World: Market Share by Anti-VEGF Drug Revenue in 2022
Figure 25. Anti-VEGF Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 26. Product Picture of Age-related Macular Degeneration
Figure 27. Global Age-related Macular Degeneration Sales YoY Growth (2018-2029) & (K Units)
Figure 28. Product Picture of Macular Edema Following Retinal Vein Occlusion
Figure 29. Global Macular Edema Following Retinal Vein Occlusion Sales YoY Growth (2018-2029) & (K Units)
Figure 30. Product Picture of Diabetic Macular Edema
Figure 31. Global Diabetic Macular Edema Sales YoY Growth (2018-2029) & (K Units)
Figure 32. Product Picture of Diabetic Retinopathy
Figure 33. Global Diabetic Retinopathy Sales YoY Growth (2018-2029) & (K Units)
Figure 34. Global Anti-VEGF Drug Sales by Application (2018-2029) & (US$ Million)
Figure 35. Global Anti-VEGF Drug Sales Market Share by Application in 2022 & 2029
Figure 36. North America Anti-VEGF Drug Sales Market Share in Volume by Application in 2022
Figure 37. North America Anti-VEGF Drug Sales Market Share in Value by Application in 2022
Figure 38. Europe Anti-VEGF Drug Sales Market Share in Volume by Application in 2022
Figure 39. Europe Anti-VEGF Drug Sales Market Share in Value by Application in 2022
Figure 40. Asia-Pacific Anti-VEGF Drug Sales Market Share in Volume by Application in 2022
Figure 41. Asia-Pacific Anti-VEGF Drug Sales Market Share in Value by Application in 2022
Figure 42. Latin America Anti-VEGF Drug Sales Market Share in Volume by Application in 2022
Figure 43. Latin America Anti-VEGF Drug Sales Market Share in Value by Application in 2022
Figure 44. Middle East and Africa Anti-VEGF Drug Sales Market Share in Value by Application in 2022
Figure 45. Key Raw Materials Price
Figure 46. Anti-VEGF Drug Manufacturing Cost Structure
Figure 47. Anti-VEGF Drug Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries